Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NEJM publishes Novartis Afinitor Phase I/II study results
Data from Phase I/II study showed that treatment with Everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent
Data from Phase I/II study showed that treatment with Everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent
Adventrx retains exclusive worldwide rights to Exelbine, other than in China, Hong Kong, Macau and Taiwan. Adventrx said that the FDA conditionally accepted Exelbine as the proposed proprietary
Biogen Idec said that the step is consistent with its strategic decision to narrow its research and development (R&D) focus and terminate its efforts in cardiovascular medicine that
The agreement combines Sony DADC’s Blu-ray Disc manufacturing technology and manufacturing capacity with Caliper’s microfluidics expertise and patent portfolio to develop enabling solutions for life science researchers and
Mannatech has posted a net loss of $1.29m for the third quarter 2010, or $0.05 loss per diluted share, compared to $9.21m, or $0.35 loss per diluted share,
The FilmArray RP is a user-friendly multiplex PCR assay, which is designed for the detection and differentiation of a panel of respiratory viruses and bacteria. Idaho Technology CEO
As per the act, the grants are awarded to therapeutic discovery projects that show reasonable potential to result in new therapies to treat areas of unmet medical need
According to the company, the grants will fund further research on new generations of the its drug delivery technologies targeting ophthalmic diseases. pSivida develops tiny drug delivery products
The agreement was signed together with Wanbang Biopharmaceuticals, as part of the D-Pharm – Wanbang co-development program for DP-b99 in China. Discovered and developed by D-Pharm, DP-b99 is
As per the terms of the agreement, Simcere receives exclusive rights to develop and commercialise BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets.